061250.KQ Hwail Pharmaceutical Co.Ltd

Healthcare Pharmaceuticals KOSDAQ
5,600 KRW
Close of Oct 30, 2026
5,320 12,500
Market cap
KRW 47.1B
P/E
25.1x
P/B
0.22x
ROE
4.7%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 061250.KQ undervalued?

Graham number
Price5,600
Graham value11,263
Discount50.3%

061250.KQ trades 50.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hwail Pharmaceutical Co.Ltd fundamental analysis

6 of 22 checks passed

ROE 0/2

Low return on equity (4.7%), below 10%.

ROA 1/1

Return on assets (4.5%) is above the industry median (3.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-134.4%) is below the industry median (6.6%).

Revenue Growth 0/2

Revenue shrank 8.6% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 995.1x against interest expense, well covered.

PE vs Market 0/1

PE (25.1x) is above the market median (11.3x).

PE vs Industry 0/1

PE (25.1x) is above the industry median (19.4x).

PBV 1/1

Price to book (0.2x) is below the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 5.6, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Hwail Pharmaceutical Co.Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hwail Pharmaceutical Co.Ltd

Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.

Full company profile